On April 16, 2026 Abbott today (NYSE: ABT) reported financial results for the first quarter ended March 31, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

First-quarter sales increased 7.8 percent on a reported basis and 3.7 percent on a comparable basis.
First-quarter GAAP diluted EPS of $0.61 and adjusted diluted EPS of $1.15, which excludes specified items and reflects growth of 6 percent.
On March 23, 2026, Abbott completed its acquisition of Exact Sciences, establishing the company as a leader in the oncology diagnostics market and adding a new high-growth vertical to Abbott’s portfolio.
Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%1.
Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences.
In January, Abbott announced a collaboration with AtaCor Medical to develop a next-generation extravascular implantable cardioverter (EV-ICD) system designed to deliver defibrillation therapy to people living with life-threatening heart rhythms.
In February, Abbott announced positive early results from the VERITAS study that show clinically meaningful closure rates of the investigational Amulet 360 Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce the risk of stroke in patients with atrial fibrillation (AFib).
In March, Abbott announced results from the FreeDM2 randomized controlled trial, demonstrating that people with Type 2 diabetes on basal insulin who used FreeStyle Libre achieved a 0.6% reduction in HbA1c and spent 2.5 more hours per day in the healthy glucose range compared to fingerstick monitoring.
"Our first-quarter results were aligned with our expectations to start the year," said Robert B. Ford, chairman and chief executive officer, Abbott. "The acquisition of Exact Sciences adds another high-growth business to the Abbott portfolio, further strengthening our confidence in delivering accelerating growth as we move through the year."

FIRST-QUARTER BUSINESS OVERVIEW

Comparable sales growth:
Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott’s Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

First Quarter 2026 Results (1Q26)

Sales 1Q26 ($ in millions)

Total Company

Nutrition

Diagnostics

Established
Pharmaceuticals

Medical Devices

U.S.

4,274

844

905

—

2,523

International

6,890

1,173

1,275

1,426

3,016

Total reported

11,164

2,017

2,180

1,426

5,539

% Change vs. 1Q25

U.S.

2.5

(11.6)

3.8

n/a

7.9

International

11.3

(1.5)

7.8

13.2

18.0

Total reported

7.8

(6.0)

6.1

13.2

13.2

Total reported excl. foreign exchange impact

3.8

(7.7)

2.5

9.0

8.1

Comparable sales growth

3.7

(7.7)

1.8

9.0

8.5

U.S.

2.5

(11.6)

2.0

n/a

8.7

International

4.6

(4.7)

1.6

9.0

8.3

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.

Nutrition

First Quarter 2026 Results (1Q26)

Sales 1Q26 ($ in millions)

Total

Pediatric

Adult

U.S.

844

511

333

International

1,173

442

731

Total reported

2,017

953

1,064

% Change vs. 1Q25

U.S.

(11.6)

(13.0)

(9.2)

International

(1.5)

(2.6)

(0.9)

Total reported

(6.0)

(8.5)

(3.6)

Total reported excl. foreign exchange impact

(7.7)

(9.7)

(5.9)

Comparable sales growth

(7.7)

(9.7)

(5.9)

U.S.

(11.6)

(13.0)

(9.2)

International

(4.7)

(5.3)

(4.3)

Worldwide Nutrition sales decreased 6.0 percent on a reported basis and 7.7 percent on a comparable basis in the first quarter.

Results in the quarter reflect the impact of lower sales volumes compared to the prior year and the effect of strategic pricing actions implemented in the fourth quarter of 2025. These pricing actions, together with the launch of several new products, are expected to contribute to improved volume growth over the course of the year.

Diagnostics*

First Quarter 2026 Results (1Q26)

Sales 1Q26 ($ in millions)

Total

Core Laboratory

Cancer Diagnostics

Rapid/Molecular
Diagnostics

U.S.

905

347

93

465

International

1,275

925

3

347

Total reported

2,180

1,272

96

812

% Change vs. 1Q25

U.S.

3.8

4.5

n/a

(13.8)

International

7.8

9.5

n/a

2.8

Total reported

6.1

8.1

n/a

(7.4)

Total reported excl. foreign exchange impact

2.5

3.3

n/a

(9.6)

Comparable sales growth

1.8

3.3

13.4

(9.6)

U.S.

2.0

4.5

13.2

(13.8)

International

1.6

2.8

19.2

(2.7)

*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business. On March 23, 2026, Abbott completed the acquisition of Exact Sciences. Following the acquisition, the sales of Exact Sciences are presented as Abbott’s Cancer Diagnostics business.

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.

Worldwide Diagnostics sales increased 6.1 percent on a reported basis and increased 1.8 percent on a comparable basis.

Worldwide Core Laboratory Diagnostics results were driven by growth in the U.S., Europe and Latin America. Sales of Core Laboratory diagnostic tests increased on both a year-over-year and sequential basis.

Rapid and Molecular Diagnostics results reflect lower demand for respiratory virus tests due to a weaker respiratory virus season compared to the prior year.

Results in Cancer Diagnostics reflect Abbott’s acquisition of Exact Sciences, which closed on March 23, 2026. Growth in Cancer Diagnostics was driven by double-digit growth of Cologuard and sales of Cancerguard, a multi-cancer screening test that launched last year.

Established Pharmaceuticals

First Quarter 2026 Results (1Q26)

Sales 1Q26 ($ in millions)

Total

Key Emerging
Markets

Other

U.S.

—

—

—

International

1,426

1,089

337

Total reported

1,426

1,089

337

% Change vs. 1Q25

U.S.

n/a

n/a

n/a

International

13.2

12.9

14.1

Total reported

13.2

12.9

14.1

Total reported excl. foreign exchange impact

9.0

9.4

7.9

Comparable sales growth

9.0

9.4

7.9

U.S.

n/a

n/a

n/a

International

9.0

9.4

7.9

Established Pharmaceuticals sales increased 13.2 percent on a reported basis and 9.0 percent on a comparable basis in the first quarter.

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott’s branded generics product portfolio. Sales in these geographies increased 12.9 percent on a reported basis and 9.4 percent on a comparable basis, led by double-digit growth in several countries across the Latin America and Asia Pacific regions.

Medical Devices

First Quarter 2026 Results (1Q26)

Sales 1Q26 ($ in millions)

Total

Rhythm
Management

Electro-

physiology*

Heart
Failure

Vascular

Structural
Heart*

Neuro-
modulation

Diabetes
Care

U.S.

2,523

339

378

292

291

224

177

822

International

3,016

345

410

97

486

354

66

1,258

Total reported

5,539

684

788

389

777

578

243

2,080

% Change vs. 1Q25

U.S.

7.9

11.5

13.7

11.4

8.6

(9.5)

0.7

9.8

International

18.0

22.9

19.6

25.2

10.0

25.2

27.2

16.6

Total reported

13.2

17.0

16.7

14.6

9.5

9.0

6.8

13.8

Total reported excl. foreign exchange impact

8.1

12.5

12.5

12.2

4.9

3.6

4.1

7.4

Comparable sales growth

8.5

12.5

12.5

12.2

4.9

6.8

4.1

7.4

U.S.

8.7

11.5

13.7

11.4

8.6

(3.6)

0.7

9.8

International

8.3

13.5

11.2

14.9

2.7

15.0

15.5

5.7

*Abbott’s Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on Jan. 1, 2026. As a result, $46 million of sales in the first quarter of 2025 were moved from Structural Heart to Electrophysiology.

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.

Worldwide Medical Devices sales increased 13.2 percent on a reported basis and 8.5 percent on a comparable basis in the first quarter.

Sales growth in the quarter was led by double-digit growth in Electrophysiology, Heart Failure and Rhythm Management.

In Diabetes Care, sales of continuous glucose monitors grew 14.2 percent on a reported basis and 7.6 percent on a comparable basis.

Abbott’s Financial Guidance
Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%.

Abbott projects full-year 2026 adjusted diluted earnings per share of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences.

Abbott projects second-quarter 2026 adjusted diluted earnings per share of $1.25 to $1.31.

Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott’s results in accordance with GAAP.

Abbott Declares 409th Consecutive Quarterly Dividend
On Feb. 20, 2026, the board of directors of Abbott declared the company’s quarterly dividend of $0.63 per share. Abbott’s cash dividend is payable May 15, 2026, to shareholders of record at the close of business on April 15, 2026.

Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

(Press release, Abbott, APR 16, 2026, View Source [SID1234664428])

On April 16, 2026 Bold Therapeutics, a clinical-stage biopharmaceutical company that was founded to develop and commercialize novel metallotherapeutics, reported new data highlighting the ability of its lead asset, BOLD-100, to demonstrate protective effects against chemotherapy-induced peripheral neuropathy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BOLD-100 is a first-in-class, ruthenium-based anticancer agent in Phase 2 clinical development for advanced gastrointestinal (GI) cancers in combination with the chemotherapy regimen FOLFOX. BOLD-100 plus FOLFOX improves overall survival and progression-free survival in patients, including advanced colon (mCRC), gastric (GC), and bile duct cancers (BTC). While FOLFOX is a standard-of-care therapy for GI cancers, its clinical utility is limited by acute and chronic peripheral neuropathies which present in the majority of patients. Remarkably, in the ongoing Phase 2 development of BOLD-100, significantly lower than expected incidence of oxaliplatin-induced peripheral neuropathy (OIPN) was observed in patients treated with BOLD-100 plus FOLFOX. Compared to FOLFOX alone historical benchmarks, BOLD-100 plus FOLFOX any-grade neuropathy was:

Colorectal Cancer; 14% vs 53% benchmark
Biliary tract cancer; 35% vs 58% benchmark
Gastric Cancer; 19% vs 63% benchmark
"These clinical findings are promising given the prevalence of peripheral neuropathy among patients undergoing chemotherapy," said Mark Bazett, PhD, Senior Director of Preclinical Development. "The potential to improve patient outcomes while simultaneously improving quality of life is a key differentiating characteristic of BOLD-100. Our upcoming AACR (Free AACR Whitepaper) presentation validates these important results in a range of preclinical models, and provides mechanistic understanding."

Bold Therapeutics will be attending the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual meeting later this month in San Diego from April 17-22, where they will present advanced in vivo and in vitro preclinical modelling of BOLD-100’s neuroprotection, along with mechanism of action data.

Abstract Title: Clinical-stage Anticancer Agent BOLD-100 Demonstrates Protective Effects Against Chemotherapy-Induced Peripheral Neuropathy
Session Time: April 21, 2:00 PM – 5:00 PM
Location: Poster Section 14; Poster Board 11
Presentation Number: 5753

Abstract link: View Source

Bold Therapeutics is currently advancing BOLD-100 through a global Phase 2 randomized controlled trial across sites in Canada, European Union, and South Korea. This trial is investigating BOLD-100’s anticancer efficacy but also includes important quality of life questionnaires focused on its neuroprotective potential. Please visit ClinicalTrials.gov for more information (NCT04421820).

(Press release, Bold Therapeutics, APR 16, 2026, View Source [SID1234664444])

On April 16, 2026 TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for braincancer and eye diseases, reported a Nature Communications article on the results from the Phase 1/2 expansion Arm A cohort of the GLORIA trial testing NOX-A12 + radiotherapy + anti-VEGF "triple therapy" in glioblastoma patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The article in the scientific peer-reviewed high-impact journal, Nature Communications, describes results of the expansion cohort Arm A in TME Pharma’s Phase 1/2 GLORIA trial. In this arm, chemotherapy-resistant (MGMT unmethylated) glioblastoma patients with residual tumor after surgery received NOX-A12 + radiotherapy + anti-VEGF (bevacizumab) "Triple Therapy". The authors noted that overall survival (OS) of patients receiving NOX-A12 Triple Therapy significantly outperformed two different cohorts of similar patients external to the trial who received standard of care treatment, and further noted that due to the conservative trial design, the study "likely underestimates survival compared with most contemporary trials."

As already disclosed in the March 5, 2024 press release, the GLORIA trial has been amended to allow inclusion of 100 additional patients in a randomized, controlled Phase 2 part of the trial composed of 5 additional arms (Expansion Group Arms D through H) to assess three different doses of NOX-A12 in the Triple Therapy, one dose of NOX-A12 + radiotherapy and standard of care. It is planned to initiate this Phase 2 part of the trial once appropriate partnerships are in place.

The findings described in the publication demonstrate the potential and value of TME Pharma’s NOX-A12 asset. TME Pharma remains confident in its strategy to search for a strategic partner to outlicense NOX-A12with the goal of bringing NOX-A12 to market authorization. As communicated on January 5, 2026, TME Pharma continues its active discussions with potential partners for the NOX-A12 program.

As indicated in its press release of March 9, 2026, TME Pharma’s financial runway now extends to Q2-2027, providing the company with the flexibility to identify the optimal partnership for NOX-A12.

Diede van den Ouden, CEO of TME Pharma, said: "We are encouraged by the publication in Nature Communications, which underscore the scientific validity of our approach. We remain fully committed to bringing NOX-A12 to success and believe that a strategic partnership is the optimal path forward. With our extended cash runway, we are well-positioned to continue our negotiations with potential partners."

(Press release, TME Pharma, APR 16, 2026, View Source [SID1234664460])

On April 16, 2026 AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") reported accelerating momentum in its pancreatic cancer program, underscored by Phase 3 trial planning underway, encouraging Phase 2 clinical signals, and a rapidly strengthening global regulatory and intellectual property ("IP") position.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The initiation of Phase 3 planning marks a critical step forward in our mission to bring Ampligen to patients with pancreatic cancer," said Thomas K. Equels, Chief Executive Officer of AIM. "With a growing body of positive late-stage pancreatic ductal adenocarcinoma clinical data, more than 100 subjects treated, Orphan Drug Designations in the U.S. and EU, and a strong global IP portfolio, we believe Ampligen has the potential to be a game-changing therapy in one of the most lethal cancers and a significant driver of long-term stockholder value."

The Company recently announced a strategic agreement with the PPD clinical research business of Thermo Fisher Scientific to design its planned Phase 3 clinical trial of Ampligen in late-stage pancreatic cancer. This collaboration brings world-class clinical development expertise to support trial design and positions AIM to efficiently advance Ampligen into late-stage development.

The planned Phase 3 program is supported by very positive published data from a Dutch government-approved Named Patient Program ("NPP") with Ampligen as a monotherapy in late-stage pancreatic ductal adenocarcinoma and reported encouraging data from the ongoing Phase 2 DURIPANC study, which is evaluating Ampligen in combination with AstraZeneca’s durvalumab. That ongoing study is showing promising improvement in progression-free survival and overall survival, as well as a favorable safety profile. Conducted in collaboration with AstraZeneca and Erasmus Medical Center, the study is expected to complete enrollment later this year and represents a key clinical validation step for our upcoming pivotal trial. As mentioned above, similar positive data was observed in the NPP, where Ampligen as a monotherapy was administered to 82 total patients and which had a significant positive findings on both progression-free and overall survival compared to historical controls. We believe these extremely positive data help to de-risk the path forward.

Pancreatic cancer represents a large and rapidly growing global market opportunity, with incidence rising and limited innovation over several decades. It is projected to become the second leading cause of cancer-related deaths in the United States, underscoring both the urgency and the commercial potential for new therapeutic options.

Ampligen, a selective TLR3 agonist, is designed to activate innate immunity and improve tumor responsiveness, making it a strong candidate for use as both a monotherapy and in combination with checkpoint inhibitors in multiple solid tumor types, and specifically with positive Phase 1/2 safety and efficacy data in combination with AstraZeneca’s durvalumab and Merck’s pembrolizumab in pancreatic cancer.

The Company continues to expand its global IP portfolio. AIM recently obtained final approval of a Japanese patent covering Ampligen in combination with checkpoint inhibitors, which is set to expire in 2039. Existing patents in the United States and Europe also extend to 2039, with broad claims supporting combination use across multiple oncology indications. This IP estate positions Ampligen for long-term commercial protection across major markets.

AIM’s IP portfolio includes orphan drug designations for pancreatic cancer in both the United States and Europe, and the Company announced in March 2026 that it would seek similar status in Japan. The United States, Europe and Japan are the three largest accessible pharma markets in the world – and pancreatic cancer is potentially one of the most lucrative global health markets, as it is a serious and unmet need that is expected to become an even greater health burden. These designations provide potential market exclusivity upon approval, regulatory incentives, reduced development costs, and opportunities for accelerated development pathways, reinforcing the Company’s strategy and enhancing long-term value creation.

Looking ahead, AIM anticipates several near-term milestones that may serve as significant value drivers. These include the completion of Phase 2 DURIPANC enrollment and additional data updates; continued clinical data readouts; further IP expansion and regulatory progress; the potential for new developments from existing strategic collaborations; and the design, IND approval and commencement of a Phase 3 pivotal study in pancreatic cancer.

As previously announced, Thomas K. Equels, MS JD, Chief Executive Officer of AIM, will participate in a Virtual Investor Closing Bell Event today, April 16, 2026 at 4:00 PM ET. A live video webcast of the presentation will be available on the Events page of the Company’s website (aimimmuno.com). A webcast replay will become available two hours following the live presentation and will be accessible for 90 days.

(Press release, AIM ImmunoTech, APR 16, 2026, View Source [SID1234664429])

On April 16, 2026 Elephas Biosciences Corporation (Elephas), a private company that has developed the elive ex vivo tumor profiling platform, reported a scientific collaboration with Mithrl, an AI company focused on accelerating research through its Scientific Decision Engine (SDE). Combining these innovative approaches establishes a foundation for integrating functional tumor profiling with AI-driven analysis to support more scalable and systematic discovery of novel immunotherapy response signals.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Elephas elive platform captures real-time cytokine responses from live tumor fragments of core needle biopsies. Pairing the elive platform with Mithrl’s SDE enables autonomous design and execution of multi-step scientific analyses under rigorous controls.

Along with Mithrl, Elephas will be co-presenting new data from this collaboration at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, highlighting the potential of combining real-time functional tumor profiling with multi-modal data analysis to generate biologically meaningful insights more efficiently.

Poster Presentation: Multi-agent-augmented analysis of PD-1 checkpoint inhibitor response (Abstract #5695)
Date/Time: April 20, 2026, 9:00 AM – 12:00 PM PST
Location: Section 40

Learn more on the poster here: View Source!/21436/presentation/9781

"Partnering with Mithrl enables us to more fully leverage the richness of our functional profiling data and showcase the power of Agentic AI," said Hinco Gierman, CSO of Elephas. "By integrating these data with external datasets, we’re incredibly impressed with the speed at which Mithrl is able to generate novel insights that can better understand the biology of response and generate insights that may help guide translational research and therapeutic development."

"Collaborating with Elephas allows us to pair their unprecedented real-time tumor profiling from live tumor biopsies with Mithrl’s SDE to unlock deep biological insights that would otherwise remain elusive or take months to surface. I believe this combination exemplifies the future of translational research," said Vivek Adarsh, Co-Founder and CEO of Mithrl.

(Press release, Elephas Biosciences, APR 16, 2026, View Source [SID1234664445])